Novo Nordisk A/S (NYSE:NVO) stock is plunging on Monday on disappointing headline data from its REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial program.

After the update, Novo Nordisk stock hit its 52-week low. Over the year, the stock has fallen around 48%, according to Benzinga Pro data.

The 809-subject REDEFINE 4 was an 84-week trial investigating CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to tirzepatide 15 mg, both administered once weekly and subcutaneously.

Eli Lilly and Co.’s (NYSE:LLY) tirzepatide is marketed under the Zepbound and Mounjaro brands.

Efficacy Results: CagriSema vs. Tirzepatide

When evaluating the effects of treatment, if all people adhered to treatment, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with ...